17/05/2019 03:00:00

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Corcept, Mobile TeleSystems, Healthcare Services, and American Renal and Encourages Investors to Contact the Firm

NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Corcept Therapeutics Incorporated, Mobile TeleSystems PJSC, Healthcare Services Group, Inc., and American Renal Associates Holdings, Inc.  Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff.  Additional information about each case can be found at the link provided.

Corcept Therapeutics Incorporated (NASDAQ: CORT)

Class Period: August 2, 2017 - February 5, 2019

Lead Plaintiff Deadline: May 13, 2019

The complaint alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, the complaint alleges that defendants failed to disclose to investors that: (1) the company had improperly paid doctors to promote its drug Korlym; (2) the company aggressively promoted Korlym for off-label uses; (3) the company’s sole specialty pharmacy was a related party; (4) the company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Corcept class action go to: https://bespc.com/cort/.

Mobile TeleSystems PJSC (NYSE: MBT)

Class Period: March 19, 2014 - March 7, 2019

Lead Plaintiff Deadline: May 20, 2019

The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Mobile TeleSystems and its subsidiary were involved in a scheme to pay $420 million in bribes in Uzbekistan; (2) consequently, Mobile TeleSystems knew or should have known it would be forced to pay substantial fines to the U.S. government after disclosing in 2014 that the U.S. Department of Justice and Securities and Exchange Commission were investigating its Uzbekistan operations; (3) Mobile TeleSystems’ level of cooperation with the U.S. government and remediation was lacking; (4) due to the aforementioned misconduct, Mobile TeleSystems would be forced to pay approximately $850 million in criminal penalties to the U.S. government; and (5) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

To learn more about the Mobile class action go to: https://bespc.com/mbt/.

Healthcare Services Group, Inc. (NASDAQ: HCSG)

Class Period: April 11, 2017 - March 4, 2019

Lead Plaintiff Deadline: May 21, 2019

The complaint alleges that throughout the Class Period defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies.  Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated the price of Healthcare Services securities and misrepresented the value of the company’s business and prospects by overstating its earnings and concealing the significant defects in its internal controls.

To learn more about the Healthcare Services class action go to: https://bespc.com/hcsg/.

American Renal Associates Holdings, Inc. (NYSE: ARA)

Class Period: August 10, 2016 - March 27, 2019

Lead Plaintiff Deadline: May 28, 2019

The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal’s accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission (“SEC”) investigation into the same, and increased regulatory scrutiny by the SEC; (2) American Renal’s financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018 were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the American Renal class action go to: https://bespc.com/ara/.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contacts

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com

BES_Mark.jpg

Related content
28 May - 
ARA & NTNX- Bronstein, Gewirtz & Grossman, LLC Class Ac..
28 May - 
Glancy Prongay & Murray Reminds Investors of Looming De..
28 May - 
Corcept Therapeutics to Present Data from Phase 1/2 Tri..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
InterDigital Participates in 5G Slicing and Ultra-High Throughput Demonstrations at EUCNC
2
ROHM's New Power Supply Monitoring IC with Built-In Self-Diagnostic Function that Supports Functional Safety
3
Roskill: Chromium markets suppressed with ongoing surplus ore supply.
4
Genocea Announces Pricing of $36,750,000 Public Offering of Common Stock
5
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sprint Corporation, Boston Scientific Corporation, Box, Inc. and Cloudera, Inc. and Encourages Investors to Contact the Firm

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 June 2019 07:19:27
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB7 - 2019-06-20 08:19:27 - 2019-06-20 07:19:27 - 1000 - Website: OKAY